Gilead Sciences Inc. will pay $5.1 billion to boost its stake in Galapagos NV and gain rights outside Europe to the Belgian biotechnology company’s treatments in development, in a broad research collaboration aimed at increasing growth at the drugmakers.
Under the terms of the deal, to be announced Sunday, Gilead will make a $3.95 billion payment to Galapagos. It also will invest $1.1 billion, or €140.59 a share, to increase its stake in the drugmaker to 22% from 12.3%. That represents a 20% premium to the 30-day...
I like their balm.
Seems like a desperate move but we will see. Doesn’t seem to be much out there in terms of nearly developed molecules
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: